X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
CVN424 is a first-in-class non-dopamine therapy that selectively modulates GPR6, an orphan G-protein coupled receptor, which is investigated for the treatment option for individuals with early-stage Parkinson’s disease.
Lead Product(s): CVN424
Therapeutic Area: Neurology Product Name: CVN424
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2023
Details:
CVN293 is an investigational, potent, and selective inhibitor of KCNK13 and has been implicated in many neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Alzheimer’s disease and severe age-related macular degeneration.
Lead Product(s): CVN293
Therapeutic Area: Neurology Product Name: CVN293
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis, and schizophrenia including CVN424, a first-in-class, oral, brain penetrant, non-dopaminergic, GPR6 inverse agonist in Phase 2 trial for Parkinson’s disease.
Lead Product(s): CVN424
Therapeutic Area: Neurology Product Name: CVN424
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Gates Frontier
Deal Size: $116.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 13, 2023
Details:
CVN766 is a potent antagonist of the Ox1R with high selectivity over Ox2R (>1000 fold). Ox1R has genetic links to domains of psychiatric disorders and is expressed in areas of the brain important for regulating emotion, fear, anxiety and motivation.
Lead Product(s): CVN766
Therapeutic Area: Psychiatry/Psychology Product Name: CVN766
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
CN101248, the first selective small molecule THIK-1 inhibitor, attacks neuroinflammation via THIK-1 and have observed beneficial effects on neuroinflammation with this compound.
Lead Product(s): C101248
Therapeutic Area: Neurology Product Name: C101248
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2022
Details:
C101248, Cerevance’s novel inhibitor, demonstrated a concentration-dependent inhibition of the protein in human and mouse cells expressing THIK-1 with similar potency and maximum effect as measured by thalium assays and patch-clamp experiments.
Lead Product(s): C101248
Therapeutic Area: Neurology Product Name: C101248
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2022
Details:
Under multi-year strategic research collaboration, Merck will identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $1,125.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration August 09, 2022
Details:
CVN424 showed a 1.3-hour improvement in OFF time compared to placebo (p=0.042) at four weeks. This was accompanied by an increase in ON time without Troublesome Dyskinesia, without a meaningful worsening of ON time with Troublesome Dyskinesia.
Lead Product(s): CVN424
Therapeutic Area: Neurology Product Name: CVN424
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
The proceeds will advance the company's lead Parkinson's disease plan into phase 2 and move other prospects into the clinic from earlier stages.
Lead Product(s): CVN424
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Google Ventures
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing April 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
